Literature DB >> 21525402

Breast cancer subtypes and outcome after local and regional relapse.

E Montagna1, V Bagnardi, N Rotmensz, G Viale, G Renne, G Cancello, A Balduzzi, E Scarano, P Veronesi, A Luini, S Zurrida, S Monti, M G Mastropasqua, L Bottiglieri, A Goldhirsch, M Colleoni.   

Abstract

BACKGROUND: To evaluate the outcome of breast cancer patients after locoregional recurrence (LRR) according to tumor biological features evaluated at first diagnosis and at the time of recurrence. PATIENTS AND METHODS: We collected information on all consecutive breast cancer patients operated at the European Institute of Oncology between 1994 and 2005. The tumor characteristics and subsequent outcome of patients who experienced LRR were analyzed.
RESULTS: Two hundred and seventy nine patients with LRR were identified, 197 and 82 patients with local and regional recurrence respectively. The overall discordance rate between primary cancer and LRR was 9% for estrogen receptor expression, 22% for progesterone receptor and 4% for human epidermal growth factor receptor 2. For patients with regional recurrence, the risk of distant metastasis was significantly higher compared with local relapse in case of late recurrence (hazard ratio [HR] = 2.76; 95% CI 1.31-5.85). Patients with triple-negative breast cancer at LRR experienced a higher risk of subsequent relapse (HR 2.87 [1.67-4.91]) and death (HR 2.00 [1.25-3.19]).
CONCLUSION: LRR correlates with a high risk of subsequent events and death in particular in patients with triple-negative subtype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525402     DOI: 10.1093/annonc/mdr129

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  22 in total

1.  Time-varying coefficients in a multivariate frailty model: Application to breast cancer recurrences of several types and death.

Authors:  Yassin Mazroui; Audrey Mauguen; Simone Mathoulin-Pélissier; Gaetan MacGrogan; Véronique Brouste; Virginie Rondeau
Journal:  Lifetime Data Anal       Date:  2015-05-06       Impact factor: 1.588

Review 2.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Authors:  Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

3.  Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death.

Authors:  Dong Won Ryu; Chung Han Lee
Journal:  J Korean Surg Soc       Date:  2012-09-25

4.  Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?

Authors:  Dominique Sighoko; Juxin Liu; Ningqi Hou; Paul Gustafson; Dezheng Huo
Journal:  Oncologist       Date:  2014-05-07

5.  Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery.

Authors:  Gerd Fastner; Cornelia Hauser-Kronberger; Angelika Moder; Roland Reitsamer; Franz Zehentmayr; Peter Kopp; Christoph Fussl; Thorsten Fischer; Heinrich Deutschmann; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2015-09-24       Impact factor: 3.621

6.  Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.

Authors:  Yu-Feng Yang; Ying-Yang Liao; Mei Yang; Ning-Fu Peng; Shu-Rui Xie; Yan-Fang Xie
Journal:  Med Oncol       Date:  2014-09-13       Impact factor: 3.064

7.  Factors associated with breast cancer mortality after local recurrence.

Authors:  R Dent; A Valentini; W Hanna; E Rawlinson; E Rakovitch; P Sun; S A Narod
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

8.  Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial.

Authors:  Emilia Montagna; Vincenzo Bagnardi; Giuseppe Cancello; Claudia Sangalli; Eleonora Pagan; Monica Iorfida; Manuelita Mazza; Giovanni Mazzarol; Silvia Dellapasqua; Elisabetta Munzone; Aaron Goldhirsch; Marco Colleoni
Journal:  Breast Care (Basel)       Date:  2018-04-26       Impact factor: 2.860

9.  Prognostic Factors Associated with Curing in Patients with Breast Cancer: A Joint Frailty Model.

Authors:  Freshteh Osmani; Ebrahim Hajizadeh; Mohammad Esmaeil Akbari
Journal:  Int J Prev Med       Date:  2021-01-19

10.  Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning.

Authors:  Huihui Chen; Shijie Wu; Jun Hu; Kun Zhang; Kaimin Hu; Yuexin Lu; Jiapan He; Tao Pan; Yiding Chen
Journal:  J Oncol       Date:  2021-05-15       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.